PB2073: LACK OF AGREEMENT ON EVENT-FREE SURVIVAL DEFINITION IN MARGINAL ZONE LYMPHOMA

por Bommier, C., Lambert, J., Nowakowski, G., Zucca, E., Thieblemont, C.
Publicado 2022

Upregulation of TET activity with ascorbic acid induces epigenetic modulation of lymphoma cells

por Shenoy, N, Bhagat, T, Nieves, E, Stenson, M, Lawson, J, Choudhary, G S, Habermann, T, Nowakowski, G, Singh, R, Wu, X, Verma, A, Witzig, T E
Publicado 2017

PB2113: FRONTMIND: A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TAFASITAMAB + LENALIDOMIDE + R-CHOP VS R-CHOP ALONE FOR NEWLY DIAGNOSED HIGH-INTERMEDIATE AND HIGH-RISK DIFFUSE LA...

por Vitolo, U., Nowakowski, G. S., Burke, J. M., Fox, C. P., Trneny, M., Chiappella, A., Waldron-Lynch, M., Hadar, N., Pachori, A., Lenz, G.
Publicado 2022

P1168: CHARACTERISTICS PREDICTIVE OF PROGRESSION DURING FRONTLINE TREATMENT IN AGGRESSIVE B-CELL LYMPHOMAS

por Bock, A., Mwangi, R., Maurer, M., Cerhan, J., Ng, W. L., King, R., Bennani, N. N., Ansell, S., Habermann, T., Witzig, T., Wang, Y., Nowakowski, G.
Publicado 2022

PB2110: PHARMACOKINETICS AND PHARMACODYNAMICS IN FIRST-MIND: A PHASE IB, OPEN-LABEL, RANDOMIZED STUDY OF TAFASITAMAB ± LENALIDOMIDE + R-CHOP IN PATIENTS WITH NEWLY DIAGNOSED DIFFUS...

por Belada, D., Kopeckova, K., Bergua Burgues, J. M., Stevens, D., Nowakowski, G. S., Waldron-Lynch, M., Hadar, N., Weirather, J., Lässig, C., Blair, D., Dreyling, M.
Publicado 2022

High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance)

por Witzig, T E, LaPlant, B, Habermann, T M, McPhail, E, Inwards, D J, Micallef, I N, Colgan, J P, Nowakowski, G S, Ansell, S M, Johnston, P B
Publicado 2017

P1178: BRENTUXIMAB VEDOTIN IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL: SAFETY AND EFFICACY RESULTS FROM THE SAFETY RUN-IN PERIOD OF T...

por Bartlett, N. L., Yasenchak, C. A., Ashraf, K. K., Harwin, W. N., Orcutt, J., Kuriakose, P., Zinzani, P. L., Mamidipalli, A., Fenton, K., Glenn, C., Nowakowski, G.
Publicado 2022

PB2111: SUBGROUP ANALYSIS IN RE-MIND2, AN OBSERVATIONAL, RETROSPECTIVE COHORT STUDY OF TAFASITAMAB + LENALIDOMIDE VERSUS SYSTEMIC THERAPIES IN PATIENTS WITH RELAPSED/REFRACTORY DIF...

por Nowakowski, G. S., Yoon, D. H., Joffe, E., Zinzani, P. L., Sabatelli, L., Waltl, E. E., Alvero, C. G., Hess, G., Riedell, P., Kim, K., Brixner, D., Salles, G.
Publicado 2022

P1121: TAKEAIM LYMPHOMA- AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION TRIAL OF EMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOG...

por Joffe, E., Nowakowski, G., Tun, H., Rosenthal, A., Lunning, M., Ramchandren, R., Li, C.-C., Zhou, L., Martinez, E., von Roemeling, R., Earhart, R., McMahon, M., Isufi, I., Leslie, L.
Publicado 2022

P1094: CHARACTERISTICS, MANAGEMENT, AND OUTCOMES OF PATIENTS WITH T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA AT A LARGE TERTIARY CARE CENTER

por Audil, H., Shah, M., Rabe, K., Ding, W., Hampel, P., Bennani, N. N., Call, T., Hanson, C., Wang, Y., Koehler, A., Schwager, S., Leis, J., Slager, S., Kenderian, S., Al-Kali, A., Nowakowski, G., Shi, M., Parikh, S.
Publicado 2022

P1156: MAGNIFY PHASE 3B STUDY OF LENALIDOMIDE + RITUXIMAB (R2) FOLLOWED BY MAINTENANCE IN RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA: COMPLETE INDUCTION PHASE ANALYSIS

por Lansigan, F., Andorsky, D. J., Coleman, M., Yacoub, A., Melear, J. M., Fanning, S. R., Kolibaba, K. S., Reynolds, C., Nowakowski, G. S., Gharibo, M., Ahn, J. R., Li, J., Rummel, M. J., Sharman, J. P.
Publicado 2022

Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphoma

por Porrata, L F, Ristow, K M, Habermann, T M, Macon, W R, Witzig, T E, Colgan, J P, Inwards, D J, Ansell, S M, Micallef, I N, Johnston, P B, Nowakowski, G, Thompson, C A, Markovic, S N
Publicado 2013

The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas

por Briski, R, Feldman, A L, Bailey, N G, Lim, M S, Ristow, K, Habermann, T M, Macon, W R, Inwards, D J, Colgan, J P, Nowakowski, G S, Kaminski, M S, Witzig, T E, Ansell, S M, Wilcox, R A
Publicado 2014

Genetic diversity of newly diagnosed follicular lymphoma

por Asmann, Y W, Maurer, M J, Wang, C, Sarangi, V, Ansell, S M, Feldman, A L, Nowakowski, G S, Manske, M, Price-Troska, T, Yang, Z-Z, Slager, S L, Habermann, T M, Cerhan, J R, Novak, A J
Publicado 2014

P1096: TREATMENT PATTERNS AND OUTCOMES IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA

por Bock, A., Poonsombudlert, K., Larson, M., Gile, J., Tawfiq, R., Maliske, S., Maurer, M., Cerhan, J., Andrade-gonzalez, X., Saliba, A., Paludo, J., Inwards, D., Ansell, S., Witzig, T., Habermann, T., Link, B., Ayyappan, S., Nowakowski, G., Farooq, U., Wang, Y.
Publicado 2022

Whole-exome analysis reveals novel somatic genomic alterations associated with cell of origin in diffuse large B-cell lymphoma

por Manso, B A, Wenzl, K, Asmann, Y W, Maurer, M J, Manske, M, Yang, Z-Z, Slager, S L, Nowakowski, G S, Ansell, S M, Witzig, T E, Feldman, A L, Rimsza, L, Link, B, Cerhan, J R, Novak, A J
Publicado 2017

Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma

por Tracy, S I, Maurer, M J, Witzig, T E, Drake, M T, Ansell, S M, Nowakowski, G S, Thompson, C A, Inwards, D J, Johnston, P B, Micallef, I N, Allmer, C, Macon, W R, Weiner, G J, Slager, S L, Habermann, T M, Link, B K, Cerhan, J R
Publicado 2017

Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma

por Novak, A J, Asmann, Y W, Maurer, M J, Wang, C, Slager, S L, Hodge, L S, Manske, M, Price-Troska, T, Yang, Z-Z, Zimmermann, M T, Nowakowski, G S, Ansell, S M, Witzig, T E, McPhail, E, Ketterling, R, Feldman, A L, Dogan, A, Link, B K, Habermann, T M, Cerhan, J R
Publicado 2015

Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials

por Castellino, A., Chiappella, A., LaPlant, B. R., Pederson, L. D., Gaidano, G., Macon, W. R., Inghirami, G., Reeder, C. B., Tucci, A., King, R. L., Congiu, A., Foran, J. M., Pavone, V., Rivera, C. E., Spina, M., Ansell, S. M., Cavallo, F., Molinari, A. L., Ciccone, Giovannino, Habermann, T. M., Witzig, T. E., Vitolo, U., Nowakowski, G. S.
Publicado 2018